| Literature DB >> 25524711 |
Thomas Skripuletz1, Arndt Manzel2, Karoline Gropengießer1, Nora Schäfer1, Viktoria Gudi1, Vikramjeet Singh3, Laura Salinas Tejedor3, Stefanie Jörg4, Anna Hammer4, Elke Voss1, Franca Vulinovic1, Diane Degen1, Rebecca Wolf4, De-Hyung Lee4, Refik Pul1, Darius Moharregh-Khiabani1, Wolfgang Baumgärtner5, Ralf Gold6, Ralf A Linker4, Martin Stangel7.
Abstract
Neuroprotective approaches for central nervous system regeneration have not been successful in clinical practice so far and compounds that enhance remyelination are still not available for patients with multiple sclerosis. The objective of this study was to determine potential regenerative effects of the substance cytidine-5'-diphospho (CDP)-choline in two different murine animal models of multiple sclerosis. The effects of exogenously applied CDP-choline were tested in murine myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. In addition, the cuprizone-induced mouse model of de- and remyelination was used to specifically test the hypothesis that CDP-choline directly increases remyelination. We found that CDP-choline ameliorated the disease course of experimental autoimmune encephalomyelitis and exerted beneficial effects on myelin, oligodendrocytes and axons. After cuprizone-induced demyelination, CDP-choline effectively enhanced myelin regeneration and reversed motor coordination deficits. The increased remyelination arose from an increase in the numbers of proliferating oligodendrocyte precursor cells and oligodendrocytes. Further in vitro studies suggest that this process is regulated by protein kinase C. We thus identified a new mechanism to enhance central nervous system remyelination via the choline pathway. Due to its regenerative action combined with an excellent safety profile, CDP-choline could become a promising substance for patients with multiple sclerosis as an add-on therapy.Entities:
Keywords: EAE; demyelination; neuroinflammation; oligodendrocyte; remyelination
Mesh:
Substances:
Year: 2014 PMID: 25524711 DOI: 10.1093/brain/awu358
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501